

(19)



(11)

EP 1 439 221 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
24.01.2007 Bulletin 2007/04

(51) Int Cl.:
C12N 9/16 (2006.01)
G01N 33/50 (2006.01)

C07K 16/40 (2006.01)
C12N 5/10 (2006.01)

(21) Application number: 03028083.8

(22) Date of filing: 09.12.2003

(54) PDE core construct

PDE Kern Konstrukt

Construction dérivée du noyau de PDE

(84) Designated Contracting States:
CH DE FR GB LI

(30) Priority: 17.12.2002 EP 02028057

(43) Date of publication of application:
21.07.2004 Bulletin 2004/30

(73) Proprietor: F. HOFFMANN-LA ROCHE AG
4070 Basel (CH)

(72) Inventors:

- Certa, Ulrich
4123 Allschwil (CH)
- Fingerle, Juergen
79400 Kandern (DE)
- Nelboeck-Hochstetter, Peter
4054 Basel (CH)
- Schoenfeld, Hans-Joachim
79115 Freiburg (DE)

(56) References cited:

WO-A-02/22661 WO-A-02/074992

- KOVALA TOM ET AL: "Recombinant expression of a type IV, cAMP-specific phosphodiesterase: Characterization and structure-function studies of deletion mutants" BIOCHEMISTRY, vol. 36, no. 10, 1997, pages 2968-2976, XP002278796 ISSN: 0006-2960

- KENAN YAEL ET AL: "Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 16, 21 April 2000 (2000-04-21), pages 12331-12338, XP002278797 ISSN: 0021-9258
- FISHER D A ET AL: "Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 246, no. 3, 29 May 1998 (1998-05-29), pages 570-577, XP002091360 ISSN: 0006-291X
- BOLGER G B: "THE MULTIZYME PDE4 CYCLIC ADENOSINE MONOPHOSPHATE-SPECIFIC PHOSPHODIESTERASE FAMILY: INTRACELLULAR TARGETING, REGULATION, AND SELECTIVE INHIBITION BY COMPOUNDS EXERTING ANTI-INFLAMMATORY AND ANTIDEPRESSANT ACTIONS" ADVANCES IN PHARMACOLOGY, SAN DIEGO, CA, US, vol. 44, 1998, pages 225-342, XP000906963
- GRAEME B BOLGER ET AL: "Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 328, 1997, pages 539-548, XP002150449 ISSN: 0264-6021

EP 1 439 221 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The invention relates to modified phosphodiesterase (PDE) polypeptides with altered physicochemical properties which are particularly useful in screening assays for the identification of agonists or antagonists of PDEs, the 5 polynucleotides encoding such modified PDE polypeptides, antibodies against such polypeptides, methods of preparation and uses of such polypeptides.

[0002] The phosphodiesterases (PDEs) represent a family of enzymes that catalyze the hydrolysis of the various 10 cyclic nucleoside monophosphates (including cAMP). These cyclic nucleotides have been found to act as second messengers within the cells by carrying impulses from cell surface receptors having bound various hormones and neurotransmitters to the inside of the cells. The task of phosphodiesterases is to degrade these cyclic mononucleotides once 15 their messenger role is completed thereby regulating the level of cyclic nucleotides within the cells and maintaining cyclic nucleotide homeostasis.

[0003] Ten families of PDEs have been identified, designated PDE1 to PDE10. Within each family there are two or 20 more related but distinct gene products (A, B, C, etc.) and for each of these alternative mRNA processing gives rise to multiple splice variants, identified by an additional arabic numeral in accordance with the most recent nomenclature 25 recommendation (Molecular Pharmacology 46, 399-405, 1994).

[0004] All PDE gene products identified so far have one catalytic and a least one regulatory domain. The catalytic 30 domain lies towards the carboxylic acid terminus of each PDE protein and has the greatest homology between the PDE families, being >75% homologous at the amino acid level (Perry and Higgs, Curr. Opinion Chem. Biol. 2, 472-481, 1998). Nevertheless, each of the more than 30 known PDEs have individually distinct substrate specificities, kinetic characteristics, regulatory properties and cellular and subcellular distributions (Houslay and Milligan, Trends in Biochem. Sci. 22, 217-224, 1997).

[0005] PDEs 4, 7 and 8 are highly specific for cAMP. PDEs 5, 6, 9 and 10 are selective for cGMP. PDE3s bind cAMP 35 and cGMP with similar affinity, but hydrolyse cAMP most efficiently, cGMP rather poorly. PDE3s are, therefore, negatively regulated in their cAMP hydrolysing ability by cGMP. PDEs 1 and 2 hydrolyse both cAMP and cGMP, but with PDE1 the relative efficiencies vary with isoenzyme subtype (Perry and Higgs, Curr. Opinion Chem. Biol. 2, 472-481, 1998).

[0006] The amino terminal ends of PDEs consist of the regulatory domains, which are very different both between 40 families and between variants within families. This region contains variously: a binding domain for Ca²⁺-calmodulin (CaM) in PDE1; non-catalytic cGMP-35 binding sites in PDEs 2, 5 and 6; a binding domain for the signalling G-protein transducin in PDE6. The amino terminal region also contains protein- and membrane-targeting sequences in several 45 PDE3s and PDE4s, as well as protein kinase phosphorylation sites in PDEs 1, 3, 4 and 5. These phosphorylation sites are likely to be important in regulation of catalytic activity and/or subcellular location (Perry and Higgs, Curr. Opinion Chem. Biol. 2, 472-481, 1998).

[0007] Of particular interest to this invention are the PDE4 enzymes. PDE4 enzymes share a common structure, as 50 deduced from their amino acid sequences (Beavo and Reifsnyder, Trends Pharmacol. Sci. 11, 150-155, 1990; Bolger et al., Mol. Cell Biol. 13, 6558-6571, 1993; Houslay, Sullivan and Bolger, Adv. Pharmacol. 44, 225-242, 1998). Members of each gene family (PDE4A, PDE4B, PDE4C, PDE4D) share common C-terminal regions, different for each family, and catalytic domains that for all PDE4 isoforms are very similar (84% homology over about 360 amino acids across all PDE4s; Houslay, Sullivan and Bolger, Adv. Pharmacol. 44, 225-242, 1998).

[0008] From N-terminus to catalytic region, the sequence in "long form" PDE4s can be divided into 5 regions, three 55 of which are isoform-specific (N-terminal region, linker regions 1 and 2, or LR1 and LR2) and two, more conserved regions, that are broadly similar between all isoforms, the upstream conserved regions 1 and 2 (UCR1 and UCR2). "Short form" PDE4s, e.g. PDE4A1, PDE4B2, PDE4D1, PDE4D2, lack UCR1 and LR1 plus differing amounts of the N-terminal region of UCR2. Throughout all regions are potential phosphorylation sites for a variety of kinases, including PKA (e.g. Ser 54 in human PDE4D3), mitogen activated protein kinases (e.g. Ser 487 of human PDE4B2), casein kinase II (e.g. Ser 489 of PDE4B2) and calcium-diacylglycerol dependent protein kinases (Houslay, Sullivan and Bolger, Adv. Pharmacol. 44, 225-242, 1998). Phosphorylations at some of these sites have been shown to activate the PDEs (e.g. Ser 54), others serve to inhibit. There is also evidence that some phosphorylations serve to prime the enzymes ready for subsequent activation by further phosphorylation at a different site or sites (Houslay, Sullivan and Bolger, Adv. Pharmacol. 44, 225-242, 1998). Other auto-regulatory sites may be found in the N-terminal sequence of certain PDE4s (Bolger et al., Mol. Cell Biol. 13, 6558-6571, 1993, Mc Phee et al., Biochem. J. 310, 965-974, 1995).

[0009] Specific PDE4 inhibition may be useful over a very wide range of disease areas. These include: asthma, atopic dermatitis, depression, reperfusion injury, septic shock, toxic shock, autoimmune diabetes, AIDS, Crohn's disease, 60 multiple sclerosis, cerebral ischemia, psoriasis, allograft rejection, restenosis, stroke, ulcerative colitis, cachexia, cerebral malaria, allergic rhinoconjunctivitis, osteoarthritis, rheumatoid arthritis, autoimmune encephalomyelitis (Houslay, Sullivan and Bolger, Adv. Pharmacol. 44, 225-242, 1998, WO02/074992). In the area of asthma, PDE4 inhibition helps to increase cAMP in bronchial smooth muscle, thereby producing a modest bronchodilatory effect, of use in the alleviation of asthmatic symptoms. But perhaps most importantly, inhibition of PDE4s is now a recognised method by which to

suppress immune and inflammatory cell responses (Hughes et al. *Drug Discov. Today* 2, 89-101, 1997; Torphy, *Am. J. Respir. Crit. Care Med.* 157, 351-370, 1998; Teixeira et al., *Trends Pharm. Sci.* 18, 164-171, 1997).

[0010] PDE4s play major roles in modulating the activity of virtually every cell type involved in the inflammatory process. Immune and inflammatory conditions occur when recruitment of leukocytes from the blood compartment into tissues is either uncontrolled, inappropriate, prolonged or directed against self. In asthma, rheumatoid arthritis and multiple sclerosis, infiltration of tissues with inflammatory cells is prolonged and intense, leading ultimately to severe (and self-perpetuating) damage and loss of function. Acute disregulation of the immune system occurs in such conditions as acute respiratory distress syndrome (ARDS) where an overwhelming and generalised inflammatory response can frequently lead to death. There is also substantial evidence which suggests that inflammation may play a part in defining the extent of injury resulting from reperfusion following ischaemia, at least in brain and lung (Entman and Smith, *Cardiovasc. Res.* 28, 1301-1311, 1994).

[0011] The PDE4D phosphodiesterases, which are the most preferred focus of the present invention, exist in mammals in the form of isoenzymes (which represent different molecular forms of the same enzyme polypeptide). These phosphodiesterases are localized in the cytosol of the cell and are unassociated with any known membranous structures. The PDE4D isoenzymes specifically degrade cAMP and are a common target for such pharmacological agents as antidepressants (for example, rilopram). Several splice forms of PDE4D are known. The short forms, PDE4D1 and PDE4D2, lack UCR1 and LR1 sites. Rather than these, interest of the present invention focuses on the long isoforms, of which 6 are known, namely PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D7 and PDE4D8. All of these have in common the LR1 and UCR1 sites and the domains located at the C-terminus of these sites, but they have different N-terminal domains. Isoforms PDE4D6, D7 and D8 were recently disclosed in WO02/074992.

[0012] For identification of compounds that inhibit PDE4D isoenzymes, screening assays are used that are either whole cell assays in which the cells are treated with the inhibitor and cAMP hydrolysis is measured, or in vitro assays which use purified PDE4D isoenzymes either isolated from their natural sources or from cells overexpressing recombinant PDE4D isoenzymes. Such assays are described e.g. in WO00/09504, WO01/35979, WO01/68600 and WO98/45268. WO01/35979 describes the purification of recombinant PDE4D expressed in *Saccharomyces Cerevisiae*. The use of recombinant native forms of PDE4D for the identification of PDE agonists or antagonists has the disadvantage that the PDE4D polypeptide does not have optimal physicochemical characteristics, especially with respect to aggregate formation. Aggregate formation can lead to protein precipitation and is known to potentially decrease the activity of enzymes, compared to the authentic oligomeric molecules. Thus, aggregation of the native forms of PDE4D polypeptides in screening assays aimed at identifying agonists or antagonists of PDE4D phosphodiesterase activity negatively affects the quality of these assays. In addition, the use of assays based on individual recombinant PDE4D isoforms has the disadvantage of potentially resulting in the identification of agonists or antagonists that are specific for a single isoform of a PDE4D only, instead of agonists or antagonists which act on all long or short form PDE4D isoforms together.

35 Figure 1: Specific phosphodiesterase activity for the different PDE4D isoforms D3 and D5 to D8, and the PDE4D core construct (DC).

40 Figure 2: Aggregate formation by different PDE4D isoforms and the core construct. In this figure, the gel filtration profiles of different isoforms of PDE4D (D3, D5, D6, D7, D8), and the core construct (DC) are shown. The first elution peak represents PDE4D aggregates. The pronounced shoulder in the elution profile of DC, where polypeptides of approx. 300,000 Dalton elute, indicates a decrease in aggregation of DC, as compared to the five isoforms of PDE4D.

45 Figure 3: Quantitation of aggregation of the core construct (DC) of PDE4D, and of the tubulin content of the core construct preparations. In A), the elution profile of DC is shown, with the fractions indicated on the bottom. B) shows an SDS-PAGE of the different fractions from the gel filtration. C) shows the analysis of optical densities of individual fractions corresponding to the Coomassie stained SDS-PAGE in B).

50 Figure 4: Differences in aggregation and tubulin content of different isoforms and the core construct of PDE. A) SDS-PAGE gels are shown for DC and five isoforms of PDE4D which were analysed as described above. B) The percentage of non-aggregated PDE4D is shown for the core construct and the isoforms D3 and D5 to D8, based on total PDE4D protein. DC has the highest percentage of non-aggregated PDE4D, as compared to the five isoforms. C) This figure shows the ratio between PDE4D and tubulin for DC and the isoforms D3 and D5 to D8, based on total PDE mass and total tubulin mass. As can be seen, the tubulin content of DC is significantly lower than that of the five PDE4D isoforms indicated.

55 Figure 5: Activity assay. Phosphodiesterase activity is shown both for the PDE4D core construct (DC) and PDE4D3 (D3).

Figure 6: Rolipram inhibition. Phosphodiesterase activity of the PDE4D core construct (DC) can be inhibited by Rolipram. The IC50 of DC phosphodiesterase activity by Rolipram inhibition was 0.34+/- 0.06 mM.

[0013] The term "polypeptide" as used herein, refers to a polymer of amino acids, and not to a specific length. Thus, peptides, oligopeptides and proteins are included within the definition of polypeptide.

[0014] The term "physicochemical properties" as used herein refers to the propensity of polypeptides to monomer formation, oligomer formation or aggregate formation.

[0015] The terms "aggregation" and "aggregate formation" as used herein are used interchangeably and refer to the type of association of polypeptide chains which, in contrast to oligomer formation, is an irreversible process and does not follow the law of mass interaction. Aggregation progresses in a time dependent manner and does not stop when a defined number of chains have associated. Aggregation of polypeptides can lead to protein precipitation because the molecular size of the aggregate is so dramatically increased that the solubility of the molecules is impaired. Aggregation is also known to potentially decrease the activity of the enzyme as compared to authentic oligomeric molecules.

[0016] The term "oligomer formation" as used herein refers to a reversible association of polypeptide chains whereby the ratio of oligomeric proteins and monomeric proteins at a certain protein concentration and at thermodynamic equilibrium is described by the association constant.

[0017] The term "non-aggregated" refers to polypeptides that are present either as oligomers or monomers or a mixture of oligomers and monomers at equilibrium according to the law of mass interaction.

[0018] The term "improved physicochemical properties" as used herein refers to a decrease in aggregate formation of polypeptides. For the purpose of definition, aggregate formation of the polypeptides of this invention is determined by quantitation of the fractions of a gelfiltration experiment in which aggregated PDE elutes, and of the fractions in which non-aggregated PDE elutes. The degree of aggregation is calculated in percent of non-aggregated PDE based on total (aggregated and non-aggregated) PDE. For the purpose of the definition of aggregation, aggregated PDE is considered to elute in fractions 2 to 4, in which aggregated molecules of at least 2 Mio Daltons elute, and non-aggregated PDE is considered to elute in fractions 5 to 11, corresponding to the fractions in which molecules of about 0.3 Mio Daltons elute, when the following conditions are used for gel filtration: 50 μ l of Ni-NTA agarose purified isoform preparation are injected into a Superose 12 size exclusion column (type PC3.2/30; Amersham Pharmacia Biotech), equilibrated with 50 mM TrisHCl pH 7.7, 100 mM NaCl, 0.5 mM MgCl₂ at a flow rate of 0.1 ml/min at 4 °C. Chromatograms are recorded at 278 nm. Starting from the elution volume onwards, the column eluate is collected as 50 μ l fractions.

[0019] The term "long form PDE" as used herein refers to PDE isoforms which comprise an isoform specific N-terminal domain, linker regions LR1 and/or LR2, and upstream conserved regions UCR1 and UCR2.

[0020] The term "UCR1 start" as used herein refers to the first amino acid of the UCR1 domain of PDE4D, as annotated in SEQ ID No. 1 to 7.

[0021] The term "LF1 site" as used herein refers to the first amino acid of the splice site of PDE4D as indicated in SEQ ID No. 1-7.

[0022] The term "amino acids upstream of LF1" refers to the position of an amino acid counted from the LF-1 site towards the amino terminus of the native protein.

[0023] The term "D3" as used herein refers to the PDE4D3 isoform. The term "D4" as used herein refers to the PDE4D4 isoform. The term "D5" as used herein refers to the PDE4D5 isoform. The term "D6" as used herein refers to the PDE4D6 isoform as provided by WO02/074992. The term "D7" as used herein refers to the PDE4D7 isoform as provided by WO02/074992. The term "D8" as used herein refers to the PDE4D8 isoform as provided by WO02/074992. The polypeptide sequences of the human PDE4D isoforms D3, D4, D5, D6, D7, and D8 are shown in SEQ ID No. 1 and 3-7.

[0024] The term "Ser54" as used herein refers to the Ser residue in position 54 of PDE4D3, and to the Ser residue in the respective position of any of the other PDE polypeptides. The position corresponding to Ser54 of PDE4D3 is annotated in SEQ ID No. 1 to 7 for the different isoforms and the core sequence which is common to all the PDE4D isoforms.

[0025] The term "Ser579" as used herein refers to the Ser residue in position 579 of PDE4D3, and to the Ser residue in the respective position of any of the other PDE polypeptides. The position corresponding to Ser579 of PDE4D3 is annotated in SEQ ID No. 1 to 7 for the different isoforms and the core sequence which is common to all the PDE4D isoforms.

[0026] The term "tubulin association" as used herein refers to the tubulin content of purified PDE preparations.

[0027] As used herein, the term "agonist" also refers to activators, and the term "antagonist" also refers to inhibitors of PDE phosphodiesterase activity.

[0028] The disadvantage of native recombinant PDE polypeptides resides in the formation of aggregates of the polypeptides, which gives rise to sub-optimal conditions for the identification of modulators of PDE phosphodiesterase activity in screening assays since aggregate formation is known to lead to polypeptide precipitation and to potentially impair activity of a polypeptide. The present invention is directed to the generation of long form PDE⁴ polypeptides with improved physicochemical properties which are particularly useful for the purpose of identifying agonists or antagonists of these enzymes.

[0029] The problem of aggregate formation of recombinant long form PDE4 polypeptides was overcome in the present invention by generating a polypeptide comprising a long form PDE4 polypeptide sequence with the exception of the PDE4A polypeptide sequence, with an amino-terminal deletion between the L71 splice site and the UCR1 start said polypeptide exhibiting decreased aggregate formation, as shown in Figures 2 and 3. These polypeptides have a specific activity that is comparable to the specific activity of the native recombinant proteins, as is shown in Figure 1. In a preferred embodiment, the invention provides a polypeptide comprising a long form PDE4 polypeptide sequence, with an amino-terminal deletion wherein the proportion of non-aggregated long form PDE4 in the total protein preparation is from 55 %, preferably from 60%, more preferably from 65%, most preferably from 68% to 100%, preferably to 90 %, more preferably to 80 %, most preferably to 70% of total protein, as determined by the quantitation of eluted fractions from a gel filtration of the long form PDE4 fractions. Quantitation is performed as follows: Equal volume aliquots of fractions from Size Exclusion Chromatography, run as hereinbefore described, are analyzed by SDS-PAGE (one gel per run and isoform, Figure 3). Optical densities of Coomassie stained long form PDE4 are integrated as follows: After electrophoresis the Coomassie stained polyacrylamide gel was imaged by a video imaging system (Figure 1). Optical densities of PDE bands were integrated using a Macintosh computer and the public domain software "NIH Image", version 1.61 (developed at the U.S. National Institutes of Health and available on the Internet at <http://rsb.info.nih.gov/nih-image/>). The integrated arbitrary units per PDE band as returned by the software reflect the relative PDE concentrations within the original pools. Integrated densities from PDE bands of fractions 2-4 are added up, giving a relative amount of aggregated PDE, PDE_{agg} (Figure 3). These fractions contain molecules of at least 2 Mio Daltons. Similarly, integrated densities from PDE bands of fractions 5-11 are added up, giving a relative amount of non-aggregated PDE, $PDE_{non-agg}$. In fractions 5-11, molecules in the range of 0.3 Mio Daltons elute. Relative amount of total PDE, PDE_{total} , is given by the sum of PDE_{agg} and $PDE_{non-agg}$. The percentage of non-aggregated PDE is given by the ratio of $PDE_{non-agg}$ and PDE_{total} , multiplied by 100.

[0030] In an even more preferred embodiment, the polypeptide sequence is a PDE4D polypeptide sequence, preferably a long form PDE4D polypeptide sequence.

[0031] Methods of generating amino-terminal deletion mutants of polypeptides are well known. Such deletion mutants can be generated by using site directed mutagenesis, e.g. by using PCR (Sambrook et al., Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, New York, USA).

[0032] In one embodiment of the present invention, the polypeptide comprises a PDE polypeptide sequence starting between 25 amino acids, preferably between 20 amino acids, more preferably between 15 amino acids, even more preferably between 10 amino acids, most preferably between 5 amino acids upstream of LF1 and the LF1 site.

[0033] In another embodiment the PDE long form polypeptide sequence starts at any amino acid located between the LF1 splice site and the first amino acid of the UCR1 start of the native long form PDE4 polypeptide. In the case of the most preferred embodiment of the long form PDE4 polypeptide, PDE4D, these sites are identical in all of the long form PDE4D isoforms.

[0034] In another more preferred embodiment of the present invention, the amino-terminal deletion is such that the PDE polypeptide sequence starts at the LF1 splice site of the native PDE polypeptide. This PDE polypeptide sequence is referred to as the "core construct". The core construct spans a sequence of PDE which is shared by all isoforms. The core construct sequence of PDE4D is shown in SEQ ID No. 2.

[0035] In another more preferred embodiment of the present invention, the start of the PDE polypeptide sequence is located 13 amino acids upstream of the UCR1 start of the native PDE polypeptide. The location of this position in the long form PDE4D isoforms and the core construct of PDE4D is shown in SEQ ID No. 1-7.

[0036] The basis for the generation of the above mentioned long form PDE4 polypeptide with an amino-terminal deletion and improved physicochemical characteristics can be any isoform of long form PDE4, with the exception of PDE4A. For the most preferred embodiment the long form PDE4 polypeptide sequence is an isoform of PDE4D selected from the group consisting of D3, D4, D5, D6, D7, and D8. However, the present invention also extends to further isoforms of long form PDE4D that have not yet been identified.

[0037] Also of use to the present invention are mutants of the long form PDE4 polypeptide herein before described. Of particular interest is a long form PDE4 polypeptide sequence comprising one or more mutations of Serine residues. Preferably, said Serines are mutated to either Alanine or Aspartic acid. In a most preferred embodiment, said Serine residues are selected from the group consisting of Ser54 and Ser579. Such Serines represent targets for phosphorylation of long form PDE4 polypeptides. Phosphorylation of some of these sites has been shown to activate or inhibit the phosphodiesterase activity of PDEs.

[0038] Methods of generating amino acid substitutions in polypeptides are well known to those skilled in the art of Molecular Biology, e.g. methods such as site directed mutagenesis as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, New York, USA.

[0039] In another preferred embodiment of the present invention, the long form PDE4 polypeptide hereinbefore described exhibits decreased tubulin association, thus allowing to obtain purer long form PDE4 polypeptide preparations. To determine the decrease in tubulin association, the ratio of PDE molecules per tubulin molecules in the preparation of PDE polypeptide is calculated by quantitation of SDS-PAGE. Preferably, the ratio of PDE molecules per tubulin

molecules is at least 5, preferably at least 10, more preferably at least 15, even more preferably at least 20, most preferably at least 25 molecules of PDE per molecules of tubulin. The tubulin content of PDE preparations is determined as follows: Equal volume aliquots of fractions from SEC are analyzed by SDS-PAGE (one gel per run and isoform, Figure 3). Optical densities of Coomassie stained PDE and tubulin bands are integrated as described hereinbefore for PDE aggregation quantitation. Integrated densities from PDE bands of fractions 2-11 are added up, giving a relative amount of total PDE, PDE_{total} . Likewise, integrated densities from tubulin bands of fractions 2-11 are added up, giving $tubulin_{2-11}$, and thereby the relative amount of total tubulin, $tubulin_{total}$. The ratio of PDE and tubulin (Figure 4C) is identical with the ratio of the relative amount of total PDE4D, PDE_{tot} , and relative amount of total tubulin, $tubulin_{total}$, on a mass per mass basis.

[0040] The long form PDE⁴ polypeptides from which the peptide of this invention is generated by amino-terminal deletion as hereinbefore described include polypeptides that are substantially homologous or identical to the polypeptides shown in SEQ ID No. 1-7 and have, in their native form, the phosphodiesterase activity and specificity long form of PDE⁴. In particular, these long form PDE⁴ polypeptides also include the previously published polypeptide sequences of PDE4D3 to D8 as defined in U50159 (D3), L20969 (D4), S:1059276 (D5) and the sequences for D6, D7 and D8 as disclosed in WO02/074992. As used herein, two polypeptides (or a region of the polypeptides) are substantially homologous or identical when the amino acid sequences are at least 45-55%, typically at least 70-75%, more typically at least 80-85%, and most typically greater than 90% or more homologous or identical. To determine the percent homology or identity of two amino acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one polypeptide for optimal alignment with the other polypeptide or nucleic acid molecule). The amino acid residues or nucleotides at corresponding amino acid positions are then compared. When a position in one sequence is occupied by the same amino acid residue as the corresponding position in the other sequence, then the molecules are homologous at that position. As used herein, amino acid "homology" is equivalent to amino acid "identity". The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, percent homology equals the number of identical positions/total number of positions times 100). The long form PDE⁴ polypeptide sequences of the present invention are preferably mammalian, most preferably human. The present invention also includes variants of the polypeptides hereinbefore described with deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, *Science* 247 (1990), 1306-1310, wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

[0041] The present invention provides polynucleotides that comprise polynucleotide sequences that encode the long form PDE⁴ polypeptide sequences hereinbefore described. As an example for a sequence comprised in such a polynucleotide, the polynucleotide sequence encoding the "core construct" of PDE4D is shown in SEQ ID No. 8. However, the present invention relates to all polynucleotides comprising polynucleotide sequences encoding any of the PDE polypeptide sequences hereinbefore described.

[0042] The present invention provides an expression vector or virus comprising a polynucleotide sequence that encodes the long form PDE⁴ polypeptide sequences hereinbefore described and which is capable of directing expression of the polynucleotide sequence in a compatible prokaryotic or eukaryotic host cell. The invention also provides a prokaryotic or eukaryotic host cell transformed or infected with such an expression vector or virus. The invention further provides a process for the production of such a polypeptide comprising culturing the host cell expressing the long form PDE⁴ polypeptide sequences hereinbefore described in a suitable medium so that said polypeptide is expressed, and purifying said polypeptide from the cells. In a preferred embodiment, the virus used for the expression of a modified long form PDE⁴ polypeptide is a recombinant baculovirus. Methods of generating recombinant baculoviruses for expression of recombinant proteins are well known to the man skilled in the art. Preferably, the recombinant baculovirus is based on pFASTBac as the transfer vector. The host cell of a preferred embodiment of the invention is an insect cell. Insect cells that can be infected with recombinant baculoviruses for the purpose of expressing recombinant proteins are well known in the art. The preferred process for the production of a modified long form PDE⁴ polypeptide is a process comprising culturing the insect cell expressing the long form PDE⁴ polypeptide sequences hereinbefore described in a suitable medium so that said polypeptide is expressed, and purifying said polypeptide from the insect cell. To facilitate purification, the long form PDE4 polypeptide may also comprise a tag. Different types of such tags and the methods to join them with polynucleotide sequences encoding a polypeptide are well known to the person skilled in the art, e.g. myc-tag, FLAG-tag, six Histidine tags (hereinafter referred to as 6xHis tag). A review on tagging of proteins can be found e.g. in Fritze and Anderson, *Methods in Enzymology* (2000) 327, 3-16. It is well known that such tags may be joined to either side of the polypeptide. Some tags are known which may also be removed enzymatically from the purified polypeptide, e.g. FLAG-tag fused to the amino-terminus of a protein may be removed by digestion with bovine enterokinase (Hopp, T.P.(1988) *Biotechnology*, 6, 1204-1210). In a preferred embodiment the long form PDE4 polypeptides hereinbefore described are linked at their C-terminus to a 6xHis tag. The use of such 6xHis tags for ease of purification of recombinant polypeptides, and methods of purification of 6xHis tagged polypeptides are well known (e.g. in Sisk et al. (1994) *J. Virol.*

68, 766, and Petty, K.J. (1996) in: Ausubel, F.M. et al., eds. *Current Protocols in Molecular Biology*, Vol. 2, New York: John Wiley and Sons).

[0043] In a preferred embodiment, the polypeptide of the present invention is purified. As used herein, a polypeptide is said to be "purified" when it is substantially free of cellular material when it is isolated from recombinant and non-recombinant cells. A polypeptide, however, can be joined to another polypeptide with which it is not normally associated in a cell (e.g. in a "fusion protein") and still be "purified". Preferably, the polypeptides of the present invention are purified. The polypeptides of the invention can be purified to homogeneity. It is understood, however, that preparations in which the polypeptide is not purified to homogeneity are useful. The critical feature is that the preparation allows for the desired function of the polypeptide, even in the presence of considerable amounts of other components. Thus, the invention encompasses various degrees of purity. In one embodiment, the language "substantially free of cellular material" includes preparations of the polypeptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When a polypeptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20%, less than about 10%, or less than about 5% of the volume of the polypeptide preparation.

[0044] The present invention also provides for a use of the polypeptides hereinbefore described for identifying an agonist or antagonist of phosphodiesterase activity.

[0045] The polypeptides of the present invention can be used for a process of identifying and obtaining a drug candidate for therapy of a vascular disorder, said process comprising measuring the activation or inhibition of the phosphodiesterase activity of any of the above mentioned polypeptides. Different methods for measuring phosphodiesterase activity are known, eg. from Owens et al., *Biochem. J.* (1997) 326, 53-60. Such a drug candidate may be a compound that is either an agonist or an antagonist of the phosphodiesterase activity of PDE.

[0046] The present invention also provides a screening assay for the identification of agonists or antagonists of phosphodiesterase activity comprising at least one of the above described polypeptides. In addition, the polypeptides hereinbefore described can be used for crystallization. Crystals of the polypeptides are useful for assaying the interaction of compounds with phosphodiesterases.

[0047] Furthermore, the present invention provides a kit for identifying agonists or antagonists of phosphodiesterase activity comprising at least one of the polypeptides hereinbefore described, and a radioactive or IMKP - FP phosphodiesterase kit.

[0048] The invention will be further described by the following non-limiting examples.

Examples

[0049] In the following the term "isoform" relates to the natural PDE4D splice variants D3 and D5-D8 and the invented core variant, DC.

Cloning of the PDE4D isoforms 3-8 and the core construct

Core construct:

[0050] A cDNA encoding the core fragment that is common for all the PDE4D isoforms 3-8 starting with the amino acid sequence FDV carboxyterminal to the LF1 splice site was generated by PCR using a 5' oligonucleotide with a HindIII cloning site (gatgaattcaagctttgtatgtggacaatggcaca) introducing two additional amino acids (K and L) in front of the FDV sequence. At the 3' end a set of primers was used that either generated the native sequence (gtgatatctcattatcacgtgtcaggagaacgatcatctatgaca) or added a sequence encoding 6xHis residues (gtgatatctcattatcaa tgggatgggtatggcgtgtcaggagaacgatcatctatgac) to enable rapid purification of the recombinant proteins. The cDNA encoding the core construct was cloned as a EcoRI-EcoRV fragment into the expression vector pENTR™1a (GIBCO/BRL) Isoforms (except core construct):

The DNA fragments encoding the isoform specific N-termini were generated by using synthetic oligonucleotides with terminal restriction enzyme sites for EcoRI and HindIII incorporated for directional cloning. These isoform specific DNA fragments were fused to the core construct sequence via the HindIII site introducing two additional amino acid residues (K and L). The integrity of the clones was confirmed by DNA sequencing prior to expression.

Expression of the PDE4D isoforms and the core construct in insect cells

[0051] The cDNAs were cloned into the pFASTBAC1 vector (Life Technologies. Inc) for expression in insect cells and the products were confirmed by sequencing. After recombination into the baculovirus genome the purified viral DNAs were transformed into the insect cells. Sf9 cells were cultured at 27°C in TC100 medium (BioWhittaker) with 5% (v/v)

fetal calf serum. Virus stocks were generated with a titer of 1.5×10^9 pfu/ml. For large scale production of the isoforms 1-24 L fermentations of Sf9 cells were infected with a MOI of 1.

[0052] In one example, the 6xHis tagged PDE4D polypeptides DC, D3, D5, D6, D7 and D8 were produced in Sf9 cells in 1L spinner flasks using SF1 medium in the absence of serum. Infected cells were harvested 3 days after infection with the recombinant baculoviruses.

[0053] In another example, the PDE4D core construct DC was produced in a 24 L Airlifter Fermenter with 15 L medium (SF1 with 0% serum), 0.15 L lipids and 9 L Sf9 cells. During the entire fermentation procedure the cells were cultured at pH 6.2, $27.0 \pm 0.2^\circ\text{C}$ and a pO_2 of $30.0 \pm 0.5\%$. Cells were grown for 3 days. The cell number at infection was 2.3×10^6 cells/ml. Cells were infected with 450 ml recombinant baculovirus. Cells were harvested at 68h post infection and the cell pellet as well as the concentrated supernatant stored at -80°C until further processing.

Purification of 6xHis tagged PDE4D isoforms

[0054] Sf9 cells from 1 liter culture broth, overexpressing the respective isoform, were resuspended on ice in 50 ml 50 mM HEPES pH 7.8, 300 mM NaCl 10 mM imidazole, 1 mM DTT, supplemented with protease inhibitors (one protease inhibitor cocktail tablet "complete, EDTA-free"; Roche). Opening of cells was performed by use of a 50 ml Dounce homogenizer and the homogeneous mixture was centrifuged for 1 hour at 70'000 g and 4°C (Kontrol TFT 45.94 rotor at 30'000 rpm). The supernate was filtrated through a filter with a pore size of 1.2 μm (Minisart; Sartorius, Germany) and then applied to a 6 ml Ni-NTA agarose column at 2 ml/min. After equilibration with 50 mM HEPES pH 7.8, 300 mM NaCl, 10 mM imidazole, protein was eluted with a linear 30 ml gradient from 10 to 230 mM imidazole in the same buffer. Fractions containing the PDE4D isoform as analyzed by Coomassie stained SDS-PAGE were pooled and stored frozen at -80°C . Fresh Ni-NTA agarose material was used for every different PDE4D isoform preparation in order to prevent cross contamination of isoforms.

Specific activities of 6xHis tagged PDE4D isoforms

[0055] Relative concentrations of Ni-NTA agarose purified isoform preparations were estimated by SDS-PAGE. Equal volume amounts of isoform preparations were applied to a gradient gel (4-12% NuPage; Invitrogen). After electrophoresis the Coomassie stained polyacrylamide gel was imaged by a video imaging system (Figure 1). Optical densities of PDE4D bands were integrated using a Macintosh computer and the public domain software "NIH Image", version 1.61 (developed at the U.S. National Institutes of Health and available on the Internet at <http://rsb.info.nih.gov/nih-image/>). The integrated arbitrary units per PDE4D band as returned by the software reflect the relative PDE4D concentrations within the original pools (Figure 1, "amount"). Identities of PDE4D and tubulin bands had been verified by independent SDS-PAGE, excision of corresponding bands, trypsin cleavage and identification of tryptic peptides by MALDI-MS.

[0056] Activities of equal volume amounts of 10^6 -fold diluted purified isoforms were determined by use of a commercial radioactive phosphodiesterase assay (cAMP-dependent phosphodiesterase [^3H] assay; Amersham Pharmacia Biotech), following the instructions of the manufacturer. The obtained arbitrary activity units reflect the relative PDE4D activities within the original pools (Figure 1, "activity").

[0057] Relative specific activities of PDE4D isoforms were calculated by dividing relative activity values by relative concentration values (Figure 1, "specific activity").

Qualitative investigation of aggregation by size exclusion chromatography (SEC)

[0058] 50 μl of Ni-NTA agarose purified isoform preparation was injected into a Superose 12 size exclusion column (type PC3.2/30; Amersham Pharmacia Biotech), equilibrated with 50 mM TrisHCl pH 7.7, 100 mM NaCl, 0.5 mM MgCl₂ at a flow rate of 0.1 ml/min at 4°C . Chromatograms were recorded at 278 nm. Starting from the elution volume, the column eluate was collected as 50 μl fractions (Figure 2).

Quantification of aggregates and tubulin content

[0059] Equal volume aliquots of fractions from SEC were analyzed by SDS-PAGE (one gel per run and isoform, Figure 3). Optical densities of Coomassie stained PDE4D and tubulin bands were integrated as described above. Integrated densities from PDE4D bands of fractions 2-4 were added up, giving a relative amount of aggregated PDE4D, PDE_{agg} (Figure 3). Similarly, integrated densities from PDE4D bands of fractions 5-11 were added up, giving a relative amount of non-aggregated PDE4D, PDE_{non-agg}. Relative amount of total PDE4D, PDE_{total}, is given by the sum of PDE_{agg} and PDE_{non-agg}. The percentage of non-aggregated PDE is given by the ratio of PDE_{non-agg} and PDE_{total}, multiplied by 100 (Figure 4B).

[0060] Similarly, integrated densities from tubulin bands of fractions 2-11 were added up, giving tubulin₂₋₁₁, and thereby

the relative amount of total tubulin, tubulin_{total}. The ratio of PDE and tubulin (Figure 4C) is identical with the ratio of relative amount of total PDE4D, PDE_{tot}, and relative amount of total tubulin, tubulin_{total}.

Activity assay and inhibition of phosphodiesterase activity

5 [0061] An IMAP FP-Assay was used for the determination of phosphodiesterase activity. The phosphodiesterase activity of the core construct and PDE4D3 was measured using the HEFP Phosphodiesterase Assay Kit (Molecular Devices). 2 μ l of PDE4D3 or PDE4D core construct, 2 μ l of cAMP (to a final concentration of 40 nM) and 1 μ l of test substance or carrier were incubated for 45 min on a shaker. 12 μ l of Binding Solution provided by the kit (with beads 10 diluted 1:320) were added, and the reaction mixture incubated on a shaker for 2 hours. Fluorescence polarisation of the samples was measured in a Packard BioScience Fusion a-FP HT using as an emission filter a Polarizer 535, and as an excitation filter, Fluorescein 485/20. Inhibition of the phosphodiesterase activity of the PDE4D core construct was determined using Rolipram as inhibitor, and using PDE4D core construct at 30 ng/ml.

15 SEQUENCE LISTING

[0062]

20 <110> F. Hoffmann-La Roche AG
 <120> Modified PDE4D polypeptides
 <130> case 21507
 <160> 6
 <170> PatentIn version 3.1
 <210> 1
 25 <211> 673
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> PDE4D3
 30 <222> (1)..(673)
 <223>
 <220>
 <221> LF1_splice_site
 <222> (17)..(17)
 35 <223>
 <220>
 <221> Ser579
 <222> (579)..(579)
 <223>
 40 <220>
 <221> Ser54
 <222> (54)..(54)
 <223>
 <220>
 45 <221> UCR1_site_-13
 <222> (37)..(37)
 <223>
 <220>
 <221> UCR1_start
 50 <222> (50)..(50)
 <223>
 <400> 1

Met Met His Val Asn Asn Phe Pro Phe Arg Arg His Ser Trp Ile Cys

5 1 5 10 15

Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro

10 20 25 30

Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His

15 35 40 45

Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp

20 50 55 60

Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile

25 65 70 75 80

His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser

30 85 90 95

35

40

45

50

55

Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp

100 105 110

5

Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn

115 120 125

10

Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr

130 135 140

15

Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr

145 150 155 160

20

Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu

165 170 175

25

Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln

180 185 190

30

Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val

195 200 205

35

Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Lys Lys Lys Arg Pro

210 215 220

40

Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu

225 230 235 240

45

Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp

245 250 255

50

Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val

260 265 270

55

Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met

275 280 285

His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro

290 295 300

5 Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His

305 310 315 320

10 Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln

325 330 335

15 Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr

340 345 350

20 Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val

355 360 365

25 Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu

370 375 380

30 Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu

385 390 395 400

35 Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln

405 410 415

40 Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp

420 425 430

45 Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp

435 440 445

45 Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu

50 450 455 460

46 Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val

465 470 475 480

55

His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg

485

490

495

5

Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg

500

505

510

10

Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn

515

520

525

15

Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His

530

535

540

20

Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp

545

550

555

560

25

Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile

565

570

575

30

Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln

580

585

590

35

Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly

595

600

605

40

Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr

610

615

620

45

Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr

625

630

635

640

50

Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu Glu

645

650

655

55

Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp

660

665

670

Thr

5 <210> 2
 <211> 664
 <212> PRT
 <213> Homo sapiens
 <220>
10 <221> PDE4D_core
 <222> (1)..(664)
 <223>
 <220>
 <221> LF1_splice_site
15 <222> (2)..(2)
 <223>
 <220>
 <221> UCR1_site
 <222> (35)..(35)
20 <223>
 <220>
 <221> UCR1_site_-13
 <222> (22)..(22)
 <223>
25 <220>
 <221> SER54
 <222> (39)..(39)
 <223>
 <220>
30 <221> SER579
 <222> (564)..(564)
 <223>
 <400> 2

35

40

45

50

55

Met Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp

5 1 5 10 15

Pro Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val

10 20 25 30

His Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr

15 35 40 45

Asp Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp

20 50 55 60

Ile His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala

25 65 70 75 80

Ser Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln

30 85 90 95

Asp Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile

35 100 105 110

Asn Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu

40 115 120 125

45

50

55

Thr Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln

5 130 135 140

Thr Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met

10 145 150 155 160

Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn

15 165 170 175

Gln Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu

180 185 190

20 Val Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Lys Lys Lys Arg

195 200 205

25 Pro Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser

210 215 220

30 Leu Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu

225 230 235 240

35 Asp Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His

245 250 255

40 Val Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile

260 265 270

45 Met His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile

275 280 285

50 Pro Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr

290 295 300

55 His Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val

305 310 315 320

Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe
 5 325 330 335
 Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp
 10 340 345 350
 Val Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser
 15 355 360 365
 Glu Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His
 20 370 375 380
 Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe
 25 385 390 395 400
 Gln Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile
 30 405 410 415
 Asp Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala
 35 420 425 430
 Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val
 40 435 440 445
 Leu Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met
 45 450 455 460
 Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr
 50 465 470 475 480
 Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp
 55 485 490 495
 Arg Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His
 500 505 510

Asn Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val

5 515 520 525

His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln

10 530 535 540

Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr

15 545 550 555 560

Ile Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg

20 565 570 575

Gln Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp

25 580 585 590

Gly Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp

30 595 600 605

Thr Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser

35 610 615 620

35 Thr Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu

625 630 635 640

40 Glu Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro

645 650 655

45 Asp Thr His His His His His

660

50

<210> 3

<211> 747

<212> PRT

55 <213> Homo sapiens

<220>

<221> PDE4D5

<222> (1)..(747)

5 <223>
 <220>
 <221> isoform_specific_N-terminus
 <222> (1)..(90)
10 <223>
 <220>
 <221> LF1_splice_site
 <222> (91)..(91)
 <223>
15 <220>
 <221> UCR1_site
 <222> (124)..(124)
 <223>
 <220>
 <221> UCR1_site-13
 <222> (111)..(111)
 <223>
20 <220>
 <221> Ser54
 <222> (128)..(128)
 <223>
 <220>
 <221> Ser579
 <222> (653)..(653)
25 <223>
 <400> 3

30

35

40

45

50

55

Met Ala Gln Gln Thr Ser Pro Asp Thr Leu Thr Val Pro Glu Val Asp

5 1 5 10 15

Asn Pro His Cys Pro Asn Pro Trp Leu Asn Glu Asp Leu Val Lys Ser

10 20 25 30

Leu Arg Glu Asn Leu Leu Gln His Glu Lys Ser Lys Thr Ala Arg Lys

15 35 40 45

Ser Val Ser Pro Lys Leu Ser Pro Val Ile Ser Pro Arg Asn Ser Pro

20 50 55 60

Arg Leu Leu Arg Arg Met Leu Leu Ser Ser Asn Ile Pro Lys Gln Arg

25 65 70 75 80

Arg Phe Thr Val Ala His Thr Cys Lys Leu Phe Asp Val Asp Asn Gly

40 85 90 95

30 Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser

50 100 105 110

35 Gly Leu Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser

40 115 120 125

45 Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met

50 130 135 140

45

50

55

Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile
 145 150 155 160
 5 Val Thr Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn
 10 165 170 175
 Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg
 15 180 185 190
 Ser Pro Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu
 195 200 205
 20 Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp
 210 215 220
 Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu
 225 230 235 240
 25 Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His
 245 250 255
 Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser
 35 260 265 270
 Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr
 40 275 280 285
 Gln Lys Glu Lys Glu Lys Lys Arg Pro Met Ser Gln Ile Ser Gly
 45 290 295 300
 Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro
 50 305 310 315 320
 Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu
 55 325 330 335

Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu
 5 340 345 350
 Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu
 10 355. 360 365.
 Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr
 15 370 375 380
 Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His
 385 390 395 400
 20 Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu
 405 410 415
 25 Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala
 420 425 430
 30 Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser
 435 440 445
 35 Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn
 450 455 460
 40 Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu
 465 470 475 480
 45 Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln
 485 490 495
 50 Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp
 500 505 510
 Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu
 55 515 520 525

Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser
 5 530 535 540
 Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser
 10 545 550 555 560
 Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile
 15 565 570 575
 Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met
 20 580 585 590
 Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser
 25 595 600 605
 Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp
 30 610 615 620
 Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu
 35 625 630 635 640
 Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro
 40 645 650 655
 Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe
 45 660 665 670
 Gln Phe Glu Leu Thr Leu Glu Asp Gly Glu Ser Asp Thr Glu Lys
 50 675 680 685
 Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys
 55 690 695 700
 Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu
 705 710 715 720

Gln Val Glu Glu Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu

5 725 730 735

Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr

10 740 745

15 <210> 4
 <211> 689
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> PDE4D6
 <222> (1)..(689)
 <223>
 20 <220>
 <221> isoform_specific_N-terminus
 <222> (1)..(32)
 <223>
 <220>
 25 <221> LF1_splice_site
 <222> (33)..(33)
 <223>
 <220>
 <221> UCR1_start
 30 <222> (66)..(66)
 <223>
 <220>
 <221> UCR1_start-13
 <222> (53)..(53)
 35 <223>
 <220>
 <221> Ser54
 <222> (70)..(70)
 <223>
 40 <220>
 <221> Ser579
 <222> (595)..(595)
 <223>
 <400> 4

45

50

55

Met Ala Phe Val Trp Asp Pro Leu Gly Ala Thr Val Pro Gly Pro Ser

5

1

5

10

15

Thr Arg Ala Lys Ser Arg Leu Arg Phe Ser Lys Ser Tyr Ser Lys Leu

10

20

25

30

15

Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro

35

40

45

Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His

20

50

55

60

Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp

25

30

35

40

45

50

55

65	70	75	80
Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile			
5	85	90	95
His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser			
10	100	105	110
Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp			
15	115	120	125
Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn			
20	130	135	140
Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr			
25	145	150	155
Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr			
30	165	170	175
Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu			
35	180	185	190
Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln			
40	195	200	205
Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val			
45	210	215	220
Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Glu Lys Lys Arg Pro			
50	225	230	235
Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu			
55	245	250	255
Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp			

260

265

270

Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val

5

275

280

285

Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met

10

290

295

300

His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro

15

305

310

315

320

Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His

20

325

330

335

Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln

25

340

345

350

Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr

30

355

360

365

Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val

370

375

380

35

Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu

385

390

395

400

40

Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu

405

410

415

45

Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln

420

425

430

50

Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp

435

440

445

55

Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp

	450	455	460
5	Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu		
	465	470	475
10	Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val		
	485	490	495
15	His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg		
	500	505	510
20	Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg		
	515	520	525
25	Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn		
	530	535	540
30	Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His		
	545	550	555
35	Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp		
	565	570	575
40	Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile		
	580	585	590
45	Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln		
	595	600	605
50	Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly		
	610	615	620
55	Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr		
	625	630	635
60	Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr		

	645	650	655
5	Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu Glu		
	660	665	670
10	Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp		
	675	680	685

15 **Thr**

	<210> 5
20	<211> 750
	<212> PRT
	<213> Homo sapiens
	<220>
	<221> PDE4D7
	<222> (1)..(750)
25	<223>
	<220>
	<221> isoform_specific_N-terminus
	<222> (1)..(93)
	<223>
30	<220>
	<221> LF1_splice_site
	<222> (94)..(94)
	<223>
	<220>
35	<221> UCR1_start
	<222> (127)..(127)
	<223>
	<220>
	<221> UCR1_start-13
40	<222> (114)..(114)
	<223>
	<220>
	<221> Ser54
	<222> (131)..(131)
45	<223>
	<220>
	<221> Ser579
	<222> (656)..(656)
	<223>
50	<400> 5

Met Lys Arg Asn Thr Cys Asp Leu Leu Ser Arg Ser Lys Ser Ala Ser

5 1 5 10 15

Glu Glu Thr Leu His Ser Ser Asn Glu Glu Glu Asp Pro Phe Arg Gly

10 20 25 30

Met Glu Pro Tyr Leu Val Arg Arg Leu Ser Cys Arg Asn Ile Gln Leu

15 35 40 45

20

25

30

35

40

45

50

55

Pro Pro Leu Ala Phe Arg Gln Leu Glu Gln Ala Asp Leu Lys Ser Glu
 5 50 55 60
 Ser Glu Asn Ile Gln Arg Pro Thr Ser Leu Pro Leu Lys Ile Leu Pro
 10 65 70 75 80
 Leu Ile Ala Ile Thr Ser Ala Glu Ser Ser Gly Lys Leu Phe Asp Val
 15 85 90 95
 Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser
 20 100 105 110
 Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg
 25 115 120 125
 Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro
 30 130 135 140
 Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp
 35 145 150 155 160
 Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr
 40 165 170 175
 Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro
 45 180 185 190
 Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr
 50 195 200 205
 Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu
 55 210 215 220
 Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser
 225 230 235 240

Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu
 245 250 255
 5
 Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu
 260 265 270
 10 Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro
 275 280 285
 15 Ser Pro Thr Gln Lys Glu Lys Glu Lys Lys Arg Pro Met Ser Gln
 290 295 300
 20 Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser
 305 310 315 320
 25 Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala
 325 330 335
 30 Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg Ile
 340 345 350
 35 Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr Ile
 355 360 365
 40 Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr
 370 375 380
 45 Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp Val
 385 390 395 400
 50 Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr His
 405 410 415
 55 Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu
 420 425 430

Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His Pro
 435 440 445
 5
 Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu
 450 455 460
 10 Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val Gly
 465 470 475 480
 15 Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr
 485 490 495
 20 Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu
 500 505 510
 25 Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr
 515 520 525
 30 Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp
 530 535 540
 35 Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys Ala
 545 550 555 560
 40 Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr
 565 570 575
 45 Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu
 580 585 590
 50 Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser Val
 595 600 605
 55 Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp
 610 615 620

Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp

625 630 635 640

5 Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser

645 650 655

10 Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr

660 665 670

15 Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp

675 680 685

20 Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser

690 695 700

25 Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro

705 710 715 720

30 Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu Glu Glu Ser

725 730 735

35 Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr

740 745 750

40 <210> 6

<211> 679

<212> PRT

<213> Homo sapiens

45 <220>

<221> PDE4D8

<222> (1)..(679)

<223>

<220>

50 <221> isoform_specific_N-terminus

<222> (1)..(23)

<223>

<220>

<221> LF1_splice_site

55 <222> (23)..(23)

<223>

<220>

<221> UCR1_start

<222> (56)..(56)
<223>
5 <220>
<221> UCR1_start-13
<222> (43)..(43)
<223>
<220>
<221> Ser54
<222> (60)..(60)
10 <223>
<220>
<221> Ser579
<222> (585)..(585)
<223>
15 <400> 6

20

25

30

35

40

45

50

55

Met Ser Ile Ile Met Lys Pro Arg Ser Arg Ser Thr Ser Ser Leu Arg

5 1 5 10 15

Thr Ala Glu Ala Lys Leu Phe Asp Val Asp Asn Gly Thr Ser Ala Gly

10 20 25 30

Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu Ile Leu

15 35 40 45

Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg

20 50 55 60

Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg Asn Ser

25 65 70 75 80

Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile Val Thr Pro Phe

30 85 90 95

Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe Ala Ala

35 100 105 110

Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro Met Cys

40 115 120 125

Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln

45 130 135 140

Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln

50 145 150 155 160

Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala Ser Asn

55 165 170 175

Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met
 5 180 185 190
 Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr Phe Leu
 10 195 200 205
 Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys
 15 210 215 220
 Glu Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys Lys Leu
 20 225 230 235 240
 Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe Gly Val
 25 245 250 255
 Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp Val Asn
 30 260 265 270
 Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg
 35 275 280 285
 Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp Leu Leu
 40 290 295 300
 Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu Met Thr
 45 305 310 315 320
 Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn Ile His
 50 325 330 335
 Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala
 55 340 345 350
 Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala
 355 360 365

Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln Phe Leu
370 375 380
Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser Ser Val
385 390 395 400
Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu
405 410 415
Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu
420 425 430
Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser Lys His
435 440 445
Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val
450 455 460
Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln
465 470 475 480
Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys
485 490 495
Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe
500 505 510
Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile Ser Pro
515 520 525
Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val Gly Phe
530 535 540
Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val
545 550 555 560

His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu

5 565 570 575

Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp

10 580 585 590

Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu

15 595 600 605

Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser

20 610 615 620

Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr

25 625 630 635 640

Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val Glu Glu

40 645 650 655

Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu Ala Cys Val Ile

45 660 665 670

35 Asp Asp Arg Ser Pro Asp Thr

675

40

<210> 7

<211> 809

<212> PRT

<213> Homo sapiens

45

<220>

<221> PDE4D4

<222> (1)..(809)

<223>

50

<220>

<221> LF1_splice_site

<222> (153)..(153)

<223>

<220>

<221> UCR_1_start

55

<222> (186)..(186)

<223>

<220>

<221> UCR1_start_-13

<222> (173)..(173)

<223>

<220>

<221> Ser54

5 <222> (190)..(190)

<223>

<220>

<221> Ser579

10 <222> (715)..(715)

<223>

<400> 7

15 Met Glu Ala Glu Gly Ser Ser Ala Pro Ala Arg Ala Gly Ser Gly Glu

1

5

10

15

20

25

30

35

40

45

50

55

Gly Ser Asp Ser Ala Gly Gly Ala Thr Leu Lys Ala Pro Lys His Leu
 5 20 25 30
 Trp Arg His Glu Gln His His Gln Tyr Pro Leu Arg Gln Pro Gln Phe
 10 35 40 45
 Arg Leu Leu His Pro His His His Leu Pro Pro Pro Pro Pro Ser
 15 50 55 60
 Pro Gln Pro Gln Pro Gln Cys Pro Leu Gln Pro Pro Pro Pro Pro Pro
 20 65 70 75 80
 Leu Pro Pro Pro Pro Pro Pro Gly Ala Ala Arg Gly Arg Tyr Ala
 25 85 90 95
 Ser Ser Gly Ala Thr Gly Arg Val Arg His Arg Gly Tyr Ser Asp Thr
 30 100 105 110
 Glu Arg Tyr Leu Tyr Cys Arg Ala Met Asp Arg Thr Ser Tyr Ala Val
 35 115 120 125
 Glu Thr Gly His Arg Pro Gly Leu Lys Lys Ser Arg Met Ser Trp Pro
 40 130 135 140
 Ser Ser Phe Gln Gly Leu Arg Arg Phe Asp Val Asp Asn Gly Thr Ser
 45 145 150 155 160
 Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu
 50 165 170 175
 Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu
 55 180 185 190
 Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg
 195 200 205

Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile Val Thr
 5 210 215 220
 Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe
 10 225 230 235 240
 Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro
 15 245 250 255
 Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala
 20 260 265 270
 Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu
 25 275 280 285
 Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala
 30 290 295 300
 Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser
 35 305 310 315 320
 Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr
 40 325 330 335
 Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys
 45 340 345 350
 Glu Lys Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys
 50 355 360 365
 Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe
 55 370 375 380
 Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp
 385 390 395 400

Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly

5 405 410 415

Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp

10 420 425 430

Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu

15 435 440 445

Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn

20 450 455 460

Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr

25 465 470 475 480

Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile

435 490 495

Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln

30 500 505 510

Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser

35 515 520 525

Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln

40 530 535 540

Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln

45 545 550 555 560

Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser

50 565 570 575

Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys

55 580 585 590

Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg
 5 595 600 605
 Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro
 10 610 615 620
 Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu
 15 625 630 635 640
 Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile
 20 645 650 655
 Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val
 25 660 665 670
 Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp
 30 675 680 685
 Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn
 35 690 695 700
 Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro
 40 705 710 715 720
 Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe
 45 725 730 735
 Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser
 50 740 745 750
 Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu
 55 755 760 765
 Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val
 770 775 780

Glu Glu Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu Ala Cys

5 785 790 795 800

Val Ile Asp Asp Arg Ser Pro Asp Thr

10 805

<210> 8

<211> 1974

<212> DNA

15 <213> Homo sapiens

<220>

<221> PDE4D_core_construct

<222> (1)..(1974)

<223>

20 <400> 8

tttgatgtgg acaatggcac atctgcggga cggagtcctt tggatccat gaccagccca. 60

25 ggatccgggc taattctcca agcaaatttt gtccacagtc aacgacggga gtccttcctg 120

tatcgatccg acagcgatta tgacctctt ccaaagtcta tgtccggaa ctcctccatt 180

30 gccagtgata tacacggaga tgacttgatt gtgactccat ttgctcaggt cttggccagt 240

ctgcgaactg tacgaaacaa ctttgctgca ttaactaatt tgcaagatcg agcacctagc 300

35 aaaagatcac ccatgtgcaa ccaaccatcc atcaacaaag ccaccataac agaggaggcc 360

taccagaaac tggccagcga gaccctggag gagctggact ggtgtctgga ccagctagag 420

40 accctacaga ccagggactc cgtcagttag atggcctcca acaagttaa aaggatgctt 480

aatcgggagc tcacccatct ctctgaaatg agtcggcttg gaaatcaagt gtcagagttt 540

45 atatcaaaca cattcttaga taagcaacat gaagtggaaa ttccttcctcc aactcagaag 600

50

55

5	gaaaaggaga aaaagaaaaag accaatgtct cagatcagt gagtcaagaa attgatgcac	660
10	agctctagtc tgactaattc aagtatccca aggtttggag ttaaaactga acaagaagat	720
15	gtccttgcca aggaactaga agatgtgaac aaatggggtc ttcatgtttt cagaatagca	780
20	gagttgtctg gtaaccggcc cttgactgtt atcatgcaca ccattttca ggaacgggat	840
25	ttattaaaaa catttaaaat tccagtagat actttaatta catactttat gactctcgaa	900
30	gaccattacc atgctgatgt ggcctatcac aacaatatcc atgctgcaga tgggtccag	960
35	tctactcatg tgctattatc tacacctgct ttggaggctg ttttacaga tttggagatt	1020
40	cttgcagcaa ttttgccag tgcaatacat gatgtagatc atcctggtgt gtccaatcaa	1080
45	tttctgatca atacaaactc tgaacttgcc ttgatgtaca atgattcctc agtcttagag	1140
50	aaccatcatt tggctgtggg ctttaaattt cttcaggaag aaaactgtga cattttccag	1200
55	aatttgacca aaaaacaaag acaatctta agaaaaatgg tcattgacat cgtacttgca	1260
60	acagatatgt caaaacacat gaatctactg gctgatttga agactatggg tgaaactaag	1320
65	aaagtgacaa gctctggagt tcttcttctt gataattatt ccgataggat tcaggttctt	1380
70	cagaatatgg tgcactgtgc agatctgagc aacccaacaa agcctctcca gctgtaccgc	1440
75	cagtggacgg accggataat ggaggagttc ttccgccaag gagaccgaga gagggAACgt	1500
80	ggcatggaga taagccccat gtgtgacaag cacaatgctt ccgtggaaaa atcacagggt	1560
85	ggcttcatag actatattgt tcatcccctc tggagacat gggcagacct cgtccaccct	1620
90	gacgcccagg atattttggc cactttggag gacaatcgtg aatggtagcca gagcacaatc	1680
95	cctcagagcc cctctcctgc acctgatgac ccagaggagg gccggcaggg taaaactgag	1740
100	aaattccagt ttgaactaac tttagaggaa gatggtagt cagacacggaa aaaggacagt	1800
105	ggcagtcaag tggagaagaaga cactagctgc agtgactcca agactctttg tactcaagac	1860
110	tcagagtcta ctgaaattcc ctttgcata caggttgaag aggaggcagt agggaaagaa	1920
115	gaggaaagcc agcctgaagc ctgtgtcata gatgatcggtt ctcctgacac gtaa	1974

SEQUENCE LISTING

[0063]

5 <110> F. Hoffmann-La Roche AG
 <120> Modified PDE4D polypeptides
 <130> case 21507
 <160> 6
 <170> PatentIn version 3.1
10 <210> 1
 <211> 673
 <212> PRT
 <213> Homo sapiens
 <220>
15 <221> PDE4D3
 <222> (1)..(673)
 <223>
 <220>
 <221> LF1_splice_site
20 <222> (17)..(17)
 <223>
 <220>
 <221> Ser579
 <222> (579)..(579)
25 <223>
 <220>
 <221> Ser54
 <222> (54)..(54)
 <223>
30 <220>
 <221> UCR1_site_-13
 <222> (37)..(37)
 <223>
 <220>
35 <221> UCR1_start
 <222> (50)..(50)
 <223>
 <400> 1

40

45

50

55

EP 1 439 221 B1

Met Met His Val Asn Asn Phe Pro Phe Arg Arg His Ser Trp Ile Cys

5 1 5 10 15

Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro

10 20 25 30

Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His

15 35 40 45

Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp

20 50 55 60

Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile

25 65 70 75 80

His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser

30 85 90 95

35

40

45

50

55

EP 1 439 221 B1

Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp
5 100 105 110
Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn
10 115 120 125
Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr
15 130 135 140
Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr
145 150 155 160
20 Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu
165 170 175
Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln
25 180 185 190
Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val
30 195 200 205
Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Glu Lys Lys Arg Pro
35 210 215 220
Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu
40 225 230 235 240
Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp
45 245 250 255
Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val
50 260 265 270
Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met
55 275 280 285

EP 1 439 221 B1

His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro

290 295 300

5 Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His

305 310 315 320

10 Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln

325 330 335

15 Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr

340 345 350

20 Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val

355 360 365

25 Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu

370 375 380

30 Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu

385 390 395 400

35 Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln

405 410 415

40 Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp

420 425 430

45 Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp

435 440 445

50 Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu

450 455 460

55 Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val

465 470 475 480

EP 1 439 221 B1

His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg
5 485 490 495
Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg
10 500 505 510
Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn
15 515 520 525
Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His
20 530 535 540
Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp
25 545 550 555 560
Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile
30 565 570 575
Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln
35 580 585 590
Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly
40 595 600 605
Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr
45 610 615 620
Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr
50 625 630 635 640
Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu Glu
55 645 650 655
Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp
660 665 670

Thr

5
<210> 2
<211> 664
<212> PRT
<213> Homo sapiens
10
<220>
<221> PDE4D_core
<222> (1)..(664)
<223>
<220>
15
<221> LF1_splice_site
<222> (2)..(2)
<223>
<220>
<221> UCR1_site
20
<222> (35)..(35)
<223>
<220>
<221> UCR1_site_-13
<222> (22)..(22)
25
<223>
<220>
<221> SER54
<222> (39)..(39)
<223>
30
<220>
<221> SER579
<222> (564)..(564)
<223>
<400> 2
35

40

45

50

55

EP 1 439 221 B1

Met Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp

5 1 5 10 15

Pro Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val

10 20 25 30

His Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr

15 35 40 45

Asp Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp

20 50 55 60

Ile His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala

25 65 70 75 80

Ser Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln

30 85 90 95

Asp Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile

35 100 105 110

Asn Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu

40 115 120 125

45

50

55

EP 1 439 221 B1

Thr Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln
130 135 140
5 Thr Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met
145 150 155 160
10 Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn
165 170 175
15 Gln Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu
180 185 190
20 Val Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Lys Lys Lys Arg
195 200 205
25 Pro Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser
210 215 220
30 Leu Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu
225 230 235 240
35 Asp Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His
245 250 255
40 Val Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile
260 265 270
45 Met His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile
275 280 285
50 Pro Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr
290 295 300
55 His Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val
305 310 315 320

EP 1 439 221 B1

Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe
5 325 330 335
Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp
10 340 345 350
Val Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser
15 355 360 365
Glu Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His
370 375 380
Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe
20 385 390 395 400
Gln Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile
25 405 410 415
Asp Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala
30 420 425 430
Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val
35 435 440 445
Leu Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met
40 450 455 460
Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr
45 465 470 475 480
Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp
50 485 490 495
Arg Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His
55 500 505 510

Asn Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val

5 515 520 525

His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln

10 530 535 540

Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr

15 545 550 555 560

Ile Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg

20 565 570 575

Gln Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp

25 580 585 590

Gly Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp

30 595 600 605

Thr Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser

35 610 615 620

Thr Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu

40 625 630 635 640

Glu Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro

45 645 650 655

Asp Thr His His His His His

50 660

55 <210> 3

<211> 747

<212> PRT

<213> Homo sapiens

<220>

<221> PDE4D5

<222> (1)..(747)

5 <223>
 <220>
 <221> isoform_specific_N-terminus
 <222> (1)..(90)
10 <223>
 <220>
 <221> LF1_splice_site
 <222> (91)..(91)
 <223>
15 <220>
 <221> UCR1_site
 <222> (124)..(124)
 <223>
 <220>
 <221> UCR1_site-13
 <222> (111)..(111)
 <223>
20 <220>
 <221> Ser54
 <222> (128)..(128)
 <223>
 <220>
 <221> Ser579
 <222> (653)..(653)
25 <223>
 <400> 3

30

35

40

45

50

55

Met Ala Gln Gln Thr Ser Pro Asp Thr Leu Thr Val Pro Glu Val Asp
 5 1 5 10 15
 Asn Pro His Cys Pro Asn Pro Trp Leu Asn Glu Asp Leu Val Lys Ser
 10 20 25 30
 Leu Arg Glu Asn Leu Leu Gln His Glu Lys Ser Lys Thr Ala Arg Lys
 15 35 40 45
 Ser Val Ser Pro Lys Leu Ser Pro Val Ile Ser Pro Arg Asn Ser Pro
 20 50 55 60
 Arg Leu Leu Arg Arg Met Leu Leu Ser Ser Asn Ile Pro Lys Gln Arg
 25 65 70 75 80
 Arg Phe Thr Val Ala His Thr Cys Lys Leu Phe Asp Val Asp Asn Gly
 30 85 90 95
 Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser
 35 100 105 110
 Gly Leu Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser
 40 115 120 125
 Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met
 45 130 135 140
 50
 55

EP 1 439 221 B1

Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile
145 150 155 160
5 Val Thr Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn
165 170 175
10 Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg
180 185 190
15 Ser Pro Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu
195 200 205
20 Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp
210 215 220
25 Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu
225 230 235 240
30 Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His
245 250 255
35 Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser
260 265 270
40 Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr
275 280 285
45 Gln Lys Glu Lys Glu Lys Lys Arg Pro Met Ser Gln Ile Ser Gly
290 295 300
50 Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro
305 310 315 320
55 Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu
325 330 335

EP 1 439 221 B1

Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu
5 340 345 350
Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu
10 355 360 365
Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr
15 370 375 380
Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His
385 390 395 400
Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu
20 405 410 415
Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala
25 420 425 430
Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser
30 435 440 445
Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn
35 450 455 460
Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu
40 465 470 475 480
Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln
45 485 490 495
Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp
50 500 505 510
Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu
55 515 520 525

EP 1 439 221 B1

Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser
5 530 535 540
Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser
10 545 550 555 560
Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile
565 570 575
15 Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met
580 585 590
20 Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser
595 600 605
25 Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp
610 615 620
30 Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu
625 630 635 640
35 Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro
645 650 655
40 Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe
660 665 670
45 Gln Phe Glu Leu Thr Leu Glu Asp Gly Glu Ser Asp Thr Glu Lys
675 680 685
50 Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys
690 695 700
55 Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu
705 710 715 720

Gln Val Glu Glu Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu

725

730

735

5

Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr

740

745

10

<210> 4

<211> 689

<212> PRT

15 <213> Homo sapiens

<220>

<221> PDE4D6

<222> (1)..(689)

<223>

20 <220>

<221> isoform_specific_N-terminus

<222> (1)..(32)

<223>

<220>

25 <221> LF1_splice_site

<222> (33)..(33)

<223>

<220>

<221> UCR1_start

30 <222> (66)..(66)

<223>

<220>

<221> UCR1_start-13

<222> (53)..(53)

35 <223>

<220>

<221> Ser54

<222> (70)..(70)

<223>

40 <220>

<221> Ser579

<222> (595)..(595)

<223>

45 <400> 4

45

50

55

Met Ala Phe Val Trp Asp Pro Leu Gly Ala Thr Val Pro Gly Pro Ser

5 1 5 10 15

Thr Arg Ala Lys Ser Arg Leu Arg Phe Ser Lys Ser Tyr Ser Lys Leu

10 20 25 30

Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro

15 35 40 45

Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His

20 50 55 60

Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp

25

30

35

40

45

50

55

EP 1 439 221 B1

65 70 75 80
5 Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile
His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser
10 100 105 110
Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp
15 115 120 125
Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn
20 130 135 140
Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr
25 145 150 155 160
Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr
30 165 170 175
Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu
35 180 185 190
Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln
195 200 205
40 Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val
210 215 220
45 Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Lys Lys Arg Pro
225 230 235 240
50 Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu
245 250 255
55 Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp

EP 1 439 221 B1

	260	265	270
5	Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val		
	275	280	285
10	Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met		
	290	295	300
15	His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro		
	305	310	315
20	Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His		
	325	330	335
25	Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln		
	340	345	350
30	Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr		
	355	360	365
35	Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val		
	370	375	380
40	Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu		
	385	390	395
45	Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu		
	405	410	415
50	Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln		
	420	425	430
55	Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp		
	435	440	445
60	Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp		

EP 1 439 221 B1

	450	455	460
5	Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu		
	465	470	475
10	Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val		
	485	490	495
15	His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg		
	500	505	510
20	Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg		
	515	520	525
25	Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn		
	530	535	540
30	Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His		
	545	550	555
35	Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp		
	565	570	575
40	Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile		
	580	585	590
45	Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln		
	595	600	605
50	Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly		
	610	615	620
55	Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr		
	625	630	635
55	Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr		

	645	650	655
5	Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu Glu		
	660	665	670
10	Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp		
	675	680	685

15 Thr

20	<210> 5 <211> 750 <212> PRT <213> Homo sapiens <220> <221> PDE4D7 <222> (1)..(750) <223> <220> <221> isoform_specific_N-terminus <222> (1)..(93)
25	<223> <220> <221> LF1_splice_site <222> (94)..(94) <223>
30	<220> <221> UCR1_start <222> (127)..(127) <223> <220>
35	<221> UCR1_start-13 <222> (114)..(114) <223> <220>
40	<221> Ser54 <222> (131)..(131) <223> <220>
45	<221> Ser579 <222> (656)..(656) <223>
50	<400> 5

EP 1 439 221 B1

Met Lys Arg Asn Thr Cys Asp Leu Leu Ser Arg Ser Lys Ser Ala Ser

5 1 . 5 10 15

Glu Glu Thr Leu His Ser Ser Asn Glu Glu Glu Asp Pro Phe Arg Gly

10 20 25 30

Met Glu Pro Tyr Leu Val Arg Arg Leu Ser Cys Arg Asn Ile Gln Leu

15 35 40 45

20

25

30

35

40

45

50

55

EP 1 439 221 B1

Pro Pro Leu Ala Phe Arg Gln Leu Glu Gln Ala Asp Leu Lys Ser Glu
5 50 55 60
Ser Glu Asn Ile Gln Arg Pro Thr Ser Leu Pro Leu Lys Ile Leu Pro
10 65 70 75 80
Leu Ile Ala Ile Thr Ser Ala Glu Ser Ser Gly Lys Leu Phe Asp Val
15 85 90 95
Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser
20 100 105 110
Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg
25 115 120 125
Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro
30 130 135 140
Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp
35 145 150 155 160
Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr
40 165 170 175
Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro
45 180 185 190
Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr
50 195 200 205
Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu
55 210 215 220
Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser
225 230 235 240

EP 1 439 221 B1

Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu
245 250 255
5 Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu
260 265 270
10 Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro
275 280 285
15 Ser Pro Thr Gln Lys Glu Lys Glu Lys Lys Arg Pro Met Ser Gln
290 295 300
20 Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser
305 310 315 320
25 Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala
325 330 335
30 Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg Ile
340 345 350
35 Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr Ile
355 360 365
40 Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr
370 375 380
45 Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp Val
385 390 395 400
50 Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr His
405 410 415
55 Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu
420 425 430

EP 1 439 221 B1

Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His Pro
5 435 440 445
Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu
10 450 455 460
Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val Gly
15 465 470 475 480
Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr
20 485 490 495
Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu
25 500 505 510
Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr
30 515 520 525
Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp
35 530 535 540
Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys Ala
40 545 550 555 560
Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr
45 565 570 575
Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu
50 580 585 590
Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser Val
55 595 600 605
Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp
610 615 620

EP 1 439 221 B1

Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp

5 625 630 635 640

Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser

10 645 650 655

Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr

15 660 665 670

Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp

20 675 680 685

Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser

25 690 695 700

Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro

30 705 710 715 720

Leu Asp Glu Gln Val Glu Glu Ala Val Gly Glu Glu Glu Ser

35 725 730 735

Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr

40 740 745 750

45 <210> 6

<211> 679

<212> PRT

<213> Homo sapiens

<220>

<221> PDE4D8

<222> (1)..(679)

<223>

<220>

<221> isoform_specific_N-terminus

<222> (1)..(23)

<223>

<220>

<221> LF1_splice_site

<222> (23)..(23)

<223>

<220>
<221> UCR1_start
<222> (56)..(56)
<223>
5 <220>
<221> UCR1_start-13
<222> (43)..(43)
<223>
<220>
10 <221> Ser54
<222> (60)..(60)
<223>
<220>
<221> Ser579
15 <222> (585)..(585)
<223>
<400> 6

20

25

30

35

40

45

50

55

EP 1 439 221 B1

Met Ser Ile Ile Met Lys Pro Arg Ser Arg Ser Thr Ser Ser Leu Arg

5 1 5 10 15

Thr Ala Glu Ala Lys Leu Phe Asp Val Asp Asn Gly Thr Ser Ala Gly

10 20 25 30

Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu Ile Leu

15 35 40 45

Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg

20 50 55 60

Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg Asn Ser

25 65 70 75 80

Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile Val Thr Pro Phe

30 85 90 95

Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe Ala Ala

35 100 105 110

Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro Met Cys

40 115 120 125

Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln

45 130 135 140

Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln

50 145 150 155 160

Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala Ser Asn

55 165 170 175

EP 1 439 221 B1

Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met
5 180 185 190
Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr Phe Leu
10 195 200 205
Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys
15 210 215 220
Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys Lys Leu
225 230 235 240
Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe Gly Val
20 245 250 255
Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp Val Asn
25 260 265 270
Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg
30 275 280 285
Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp Leu Leu
35 290 295 300
Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu Met Thr
40 305 310 315 320
Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn Ile His
45 325 330 335
Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala
50 340 345 350
Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala
55 355 360 365

EP 1 439 221 B1

Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln Phe Leu
5 370 375 380
Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser Ser Val
10 385 390 395 400
Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu
15 405 410 415
Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu
20 420 425 430
Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser Lys His
25 435 440 445
Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val
30 450 455 460
Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln
35 465 470 475 480
Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys
40 485 490 495
Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe
45 500 505 510
Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile Ser Pro
50 515 520 525
Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val Gly Phe
55 530 535 540
Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val
560
545 550 555

EP 1 439 221 B1

His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu

5 565 570 575

Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp

10 580 585 590

Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu

15 595 600 605

Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser

20 610 615 620

Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr

25 625 630 635 640

Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val Glu Glu

30 645 650 655

Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu Ala Cys Val Ile

660 665 670

35 Asp Asp Arg Ser Pro Asp Thr

675

40

<210> 7

<211> 809

<212> PRT

45 <213> Homo sapiens

<220>

<221> PDE4D4

<222> (1)..(809)

<223>

50 <220>

<221> LF1_splice_site

<222> (153)..(153)

<223>

<220>

55 <221> UCR_1_start

<222> (186)..(186)

<223>

<220>

EP 1 439 221 B1

<221> UCR1_start_-13
<222> (173)..(173)

5 <223>
<220>

<221> Ser54
<222> (190)..(190)
<223>
<220>
10 <221> Ser579
<222> (715)..(715)
<223>
<400> 7

15 Met Glu Ala Glu Gly Ser Ser Ala Pro Ala Arg Ala Gly Ser Gly Glu

1

5

10

15

20

25

30

35

40

45

50

55

EP 1 439 221 B1

Gly Ser Asp Ser Ala Gly Gly Ala Thr Leu Lys Ala Pro Lys His Leu
20 25 30
5
Trp Arg His Glu Gln His His Gln Tyr Pro Leu Arg Gln Pro Gln Phe
35 40 45
10 Arg Leu Leu His Pro His His His Leu Pro Pro Pro Pro Pro Pro Ser
50 55 60
15 Pro Gln Pro Gln Pro Gln Cys Pro Leu Gln Pro Pro Pro Pro Pro Pro
65 70 75 80
20 Leu Pro Pro Pro Pro Pro Pro Gly Ala Ala Arg Gly Arg Tyr Ala
85 90 95
25 Ser Ser Gly Ala Thr Gly Arg Val Arg His Arg Gly Tyr Ser Asp Thr
100 105 110
30 Glu Arg Tyr Leu Tyr Cys Arg Ala Met Asp Arg Thr Ser Tyr Ala Val
115 120 125
35 Glu Thr Gly His Arg Pro Gly Leu Lys Lys Ser Arg Met Ser Trp Pro
130 135 140
40 Ser Ser Phe Gln Gly Leu Arg Arg Phe Asp Val Asp Asn Gly Thr Ser
145 150 155 160
45 Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu
165 170 175
50 Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu
180 185 190
55 Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg
195 200 205

EP 1 439 221 B1

Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile Val Thr
210 215 220
5 Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe
225 230 235 240
10 Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro
245 250 255
15 Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala
260 265 270
20 Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu
275 280 285
25 Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala
290 295 300
30 Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser
305 310 315 320
35 Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr
325 330 335
40 Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys
340 345 350
45 Glu Lys Glu Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys
355 360 365
50 Lys Leu Met His Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe
370 375 380
55 Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp
385 390 395 400

EP 1 439 221 B1

Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly
5 405 410 415
Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp
10 420 425 430
Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu
15 435 440 445
Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn
450 455 460
Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr
20 465 470 475 480
Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile
25 485 490 495
Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln
30 500 505 510
Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser
35 515 520 525
Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln
40 530 535 540
Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln
45 545 550 555 560
Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser
50 565 570 575
Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys
55 580 585 590

EP 1 439 221 B1

Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg
5 595 600 605
Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro
10 610 615 620
Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu
15 625 630 635 640
Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile
645 650 655
20 Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val
660 665 670
Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp
25 675 680 685
Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn
30 690 695 700
Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro
35 705 710 715 720
Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe
40 725 730 735
Glu Leu Thr Leu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser
45 740 745 750
Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu
50 755 760 765
Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val
55 770 775 780

Glu Glu Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu Ala Cys

5 785 790 795 800

Val Ile Asp Asp Arg Ser Pro Asp Thr

10 805

<210> 8

15 <211> 1974

<212> DNA

<213> Homo sapiens

<220>

20 <221> PDE4D_core_construct

<222> (1)..(1974)

<223>

<400> 8

25 tttgatgtgg acaatggcac atctgcggga cggagtcctt tggatccat gaccagccca 60

ggatccgggc taattctcca agcaaatttt gtccacagtc aacgacggga gtccttcctg 120

30 tatcgatccg acagcgatta tgacctctct ccaaagtcta tgtcccgaa ctcctccatt 180

gccagtgata tacacggaga tgacttgatt gtgactccat ttgctcaggt cttggccagt 240

35 ctgcgaactg tacgaaacaa ctttgctgca ttaactaatt tgcaagatcg agcacctagc 300

aaaagatcac ccatgtgcaa ccaaccatcc atcaacaaag ccaccataac agaggaggcc 360

40 taccagaaac tggccagcga gaccctggag gagctggact ggtgtctgga ccagctagag 420

accctacaga ccaggcactc cgtcagttagt atggcctcca acaagttaa aaggatgctt 480

45 aatcgggagc tcacccatct ctctgaaatg agtcggctcg gaaatcaagt gtcagagtt 540

atatcaaaca cattcttaga taagcaacat gaagtggaaa ttccttctcc aactcagaag 600

50

55

EP 1 439 221 B1

5	gaaaaggaga aaaagaaaaag accaatgtct cagatcaagt gaggtaagaa attgatgcac	660
10	agctctagtc tgactaattc aagtatccca aggtttggag ttaaaaactga acaagaagat gtccttgcca aggaactaga agatgtgaac aaatgggtc ttcatgttt cagaatagca	720 780
15	gagttgtctg gtaaccggcc cttgactgtt atcatgcaca ccattttca ggaacggat ttattaaaaa catttaaaat tccagtagat actttaatta catacttat gactctcgaa	840 900
20	gaccattacc atgctgatgt ggcctatcac aacaatatcc atgctgcaga tgggtccag tctactcatg tgctattatc tacacctgct ttggaggctg ttttacaga tttggagatt	960 1020
25	cttgcagcaa ttttgccag tgcaatacat gatgttagatc atcctgggt gtccaatcaa aatttgacca aaaaacaag acaatctta aggaaaatgg tcattgacat cgtacttgca	1080 1260
30	acagatatgt caaaacacat gaatctactg gctgatttga agactatgg tgaaaactaag aaagtgacaa gctctggagt tcttcttctt gataattatt ccgataggat tcaggttctt	1320 1380
35	cagaatatgg tgcactgtgc agatctgagc aacccaacaa agccctctcca gctgtaccgc cagtgacgg accggataat ggaggagttc ttccgccaag gagaccgaga gagggAACGT	1440 1500
40	ggcatggaga taagccccat gtgtgacaag cacaatgctt ccgtggaaaa atcacaggtg ggcttcatag actatattgt tcatcccctc tggagacat gggcagacct cgtccaccct	1560 1620
45	gacgcccagg atattttgga cactttggag gacaatcgta aatggtagca gagcacaatc cctcagagcc cctctcctgc acctgatgac ccagaggagg gcccggcagg tcaaactgag	1680 1740
50	aaattccagt ttgaactaac ttttagaggaa gatggtagt cagacacgga aaaggacagt ggcagtcaag tggagaagaaga cactagctgc agtgactcca agactcttg tactcaagac	1800 1860
55	tcagagtcta ctgaaattcc cttttagtggaa caggttgaag aggaggcagt agggaaagaa gagggaaagcc agcctgaagc ctgtgtcata gatgatcgat ctcctgacac gtaa	1920 1974

Claims

1. A polypeptide comprising a long form PDE4 polypeptide sequence with an amino-terminal deletion, wherein the polypeptide sequence starts at any amino acid located between the LF1 splice site and the first amino acid of the UCR1 start of the native long form PDE4 polypeptide, said polypeptide exhibiting decreased aggregate formation.
5
2. The polypeptide of claim 1 wherein said PDE4 polypeptide sequence is a PDE4D polypeptide sequence.
3. The polypeptide of any of claims 1 to 2, wherein the polypeptide sequence starts at the LF1 splice site of the native PDE4 polypeptide.
10
4. The polypeptide of any of claims 1 to 3, wherein the PDE4 polypeptide sequence start is located 13 amino acids upstream of the UCR1 start of the native PDE4 polypeptide.
5. The polypeptide of any of claims 2 to 4 wherein the PDE4D polypeptide sequence is a sequence of an isoform selected from the group consisting of D3, D4, D5, D6, D7, and D8.
15
6. The polypeptide of claims 1 to 5 wherein said polypeptide comprises one or more mutations of Serine residues.
7. The polypeptide of claim 6 wherein said Serine residues are mutated to either Alanine or Aspartic acid.
20
8. The polypeptide of claims 6 or 7 wherein said Serine residues are selected from the group consisting of Ser residues corresponding to Ser54 and Ser579 in Seq ID No. 1.
9. The polypeptide of any one of claims 1 to 5 wherein said polypeptide exhibits decreased tubulin association.
25
10. A polynucleotide sequence encoding a polypeptide as claimed in claims 1 to 9.
11. An expression vector or virus comprising a polynucleotide sequence as claimed in claim 10 and being capable of directing expression of the polynucleotide sequence in a compatible prokaryotic or eukaryotic host cell.
30
12. A virus as claimed in claim 11 wherein the virus is a recombinant baculovirus.
13. A prokaryotic or eukaryotic host cell transformed or infected with the expression vector or virus of claims 11 or 12.
35
14. A host cell as claimed in claim 13, wherein the host cell is an insect cell.
15. A process for the production of a polypeptide as claimed in claims 1 to 9, comprising culturing the host cell of claims 13 or 14 in a suitable medium so that said polypeptide is expressed, and purifying said polypeptide from the cells.
40
16. A process for the production of a polypeptide as claimed in claim 15 wherein the host cell is an insect cell.
17. A polypeptide according to claims 1 to 9 produced by the process of claims 15 or 16.
18. A screening assay for the identification of agonists or antagonists of phosphodiesterase activity comprising at least one of the polypeptides of claims 1 to 9.
45
19. A process for identifying a drug candidate for therapy of an inflammatory disease, said process comprising measuring the activation or inhibition of the phosphodiesterase activity of any of the polypeptides claimed in claims 1 to 9.
50
20. Use of a polypeptide of claims 1 to 9 for identifying an agonist or antagonist of phosphodiesterase activity.
21. Use of a polypeptide of claims 1 to 9 for crystallization.
22. A kit for identifying agonists or antagonists of phosphodiesterase activity comprising at least one of the polypeptides of claims 1 to 9 and a radioactive or IMAP-FP phosphodiesterase kit.
55

Patentansprüche

1. Polypeptid, umfassend eine Sequenz der langen Form des PDE4-Polypeptids mit einer aminoterminalen Deletion, wobei die Polypeptidsequenz bei einer beliebigen Aminosäure beginnt, die zwischen der LF1-Spleißstelle und der ersten Aminosäure des UCR1-Startpunktes der nativen langen Form des PDE4-Polypeptids liegt, wobei das Polypeptid erniedrigte Aggregatbildung aufweist.
2. Polypeptid nach Anspruch 1, wobei die PDE4-Polypeptidsequenz eine PDE4D-Polypeptidsequenz ist.
3. Polypeptid nach einem der Ansprüche 1 bis 2, wobei die Polypeptidsequenz an der LF1-Spleißstelle des nativen PDE4-Polypeptids beginnt.
4. Polypeptid nach einem der Ansprüche 1 bis 3, wobei sich der Startpunkt der PDE4-Polypeptidsequenz 13 Aminosäuren stromaufwärts des UCR1-Startpunkts des nativen PDE4-Polypeptids befindet.
5. Polypeptid nach einem der Ansprüche 2 bis 4, wobei die PDE4D-Polypeptidsequenz die Sequenz einer Isoform ist, ausgewählt aus der Gruppe bestehend aus D3, D4, D5, D6, D7 und D8.
6. Polypeptid nach den Ansprüchen 1 bis 5, wobei das Polypeptid eine oder mehrere Mutationen von Serinresten umfasst.
7. Polypeptid nach Anspruch 6, wobei die Serinreste entweder zu Alanin oder Asparaginsäure mutiert sind.
8. Polypeptid nach den Ansprüchen 6 oder 7, wobei die Serinreste ausgewählt sind aus der Gruppe bestehend aus Serinresten, die Ser 54 und Ser 579 in Seq ID NO. 1 entsprechen.
9. Polypeptid nach einem der Ansprüche 1 bis 5, wobei das Polypeptid erniedrigte Tubulinassoziation aufweist.
10. Polynukleotidsequenz, die ein Polypeptid nach den Ansprüchen 1 bis 9 codiert.
11. Expressionsvektor oder Virus, umfassend eine Polynukleotidsequenz nach Anspruch 10 und fähig, die Expression der Polynukleotidsequenz in einer kompatiblen prokaryontischen oder eukaryontischen Wirtszelle zu steuern.
12. Virus nach Anspruch 11, wobei das Virus ein rekombinantes Baculovirus ist.
13. Prokaryontische oder eukaryontische Wirtszelle, die mit dem Expressionsvektor oder Virus nach Anspruch 11 oder 12 transformiert oder infiziert ist.
14. Wirtszelle nach Anspruch 13, wobei die Wirtszelle eine Insektenzelle ist.
15. Verfahren für die Produktion eines Polypeptids nach den Ansprüchen 1 bis 9, umfassend die Züchtung der Wirtszelle nach den Ansprüchen 13 oder 14 in einem geeigneten Medium, so dass das Polypeptid exprimiert wird, und die Reinigung des Polypeptids aus den Zellen.
16. Verfahren für die Produktion eines Polypeptids nach Anspruch 15, wobei die Wirtszelle eine Insektenzelle ist.
17. Polypeptid nach den Ansprüchen 1 bis 9, das durch das Verfahren nach den Ansprüchen 15 oder 16 produziert wurde.
18. Screening-Assay zur Identifizierung von Agonisten oder Antagonisten von Phosphodiesteraseaktivität, umfassend mindestens eines der Polypeptide nach den Ansprüchen 1 bis 9.
19. Verfahren zur Identifizierung eines Wirkstoffkandidaten zur Therapie einer entzündlichen Erkrankung, umfassend die Messung der Aktivierung oder Hemmung der Phosphodiesteraseaktivität eines der Polypeptide nach einem der Ansprüchen 1 bis 9.
20. Verwendung eines Polypeptids nach einem der Ansprüchen 1 bis 9 zur Identifizierung eines Agonisten oder Antagonisten von Phosphodiesteraseaktivität.

21. Verwendung eines Polypeptids nach den Ansprüchen 1 bis 9 zur Kristallisation.

22. Kit zur Identifizierung von Agonisten oder Antagonisten von Phosphodiesteraseaktivität, umfassend mindestens eines der Polypeptide nach den Ansprüchen 1 bis 9 und einen radioaktiven oder IMAP-FP-Phosphodiesterase-Kit.

5

Revendications

1. Polypeptide comprenant une séquence polypeptidique d'une PDE4 sous forme longue avec une délétion amino-terminale, où la séquence polypeptidique commence à un aminoacide quelconque situé entre le site d'épissage LF1 et le premier aminoacide constituant le début du domaine UCR1 du polypeptide PDE4 sous forme longue natif, ledit polypeptide présentant une quantité d'agrégats diminuée.

10. 2. Polypeptide selon la revendication 1 ladite séquence polypeptidique de PDE4 étant une séquence polypeptidique de PDE4D.

15. 3. Polypeptide selon l'une quelconque des revendications 1 à 2, la séquence polypeptidique commençant au site d'épissage LF1 du polypeptide PDE4 natif.

20. 4. Polypeptide selon l'une quelconque des revendications 1 à 3, le début de la séquence polypeptidique de PDE4 étant localisé 13 aminoacides en amont du début du domaine UCR1 du polypeptide PDE4 natif.

25. 5. Polypeptide selon l'une quelconque des revendications 2 à 4, la séquence polypeptidique de PDE4D étant une séquence d'une isoforme choisie dans le groupe constitué par D3, D4, D5, D6, D7 et D8.

6. Polypeptide selon les revendications 1 à 5, ledit polypeptide comprenant une ou plusieurs mutations de résidus de sérine.

30. 7. Polypeptide selon la revendication 6, dans lequel lesdits résidus de sérine sont mutés en alanine ou en acide aspartique.

8. Polypeptide selon les revendications 6 ou 7, dans lequel lesdits résidus de sérine sont choisis dans le groupe constitué par les résidus de sérine correspondant à Ser54 et Ser579 dans SEQ ID n° : 1.

35. 9. Polypeptide selon l'une quelconque des revendications 1 à 5, ledit polypeptide présentant une association à la tubuline diminuée.

10. Séquence de polynucléotide codant pour un polypeptide selon les revendications 1 à 9.

40. 11. Vecteur d'expression ou virus comprenant une séquence de polynucléotide selon la revendication 10 et capable de diriger l'expression de la séquence de polynucléotide dans une cellule hôte procaryote ou eucaryote compatible.

12. Virus selon la revendication 11, le virus étant un baculovirus recombiné.

45. 13. Cellule hôte procaryote ou eucaryote transformée ou infectée par le vecteur d'expression ou le virus des revendications 11 ou 12.

14. Cellule hôte selon la revendication 13, la cellule hôte étant une cellule d'insecte.

50. 15. Procédé pour la production d'un polypeptide selon les revendications 1 à 9 comprenant la culture de la cellule hôte des revendications 13 ou 14 dans un milieu approprié de telle sorte que ledit polypeptide soit exprimé, et la purification dudit polypeptide à partir des cellules.

55. 16. Procédé pour la production d'un polypeptide selon la revendication 15, dans lequel la cellule hôte est une cellule d'insecte.

17. Polypeptide selon les revendications 1 à 9, produit par le procédé selon les revendications 15 ou 16.

18. Test de criblage pour l'identification d'agonistes ou d'antagonistes de l'activité phosphodiésterase comprenant au moins un des polypeptides selon les revendications 1 à 9.

5 19. Procédé pour l'identification d'un médicament candidat pour la thérapie d'une maladie inflammatoire, ledit procédé comprenant la mesure de l'activation ou de l'inhibition de l'activité phosphodiésterase d'un quelconque des peptides selon les revendications 1 à 9.

10 20. Utilisation d'un polypeptide selon les revendications 1 à 9, pour identifier un agoniste ou un antagoniste de l'activité phosphodiésterase.

21. Utilisation d'un polypeptide selon les revendications 1 à 9 pour la cristallisation.

15 22. Trousse pour l'identification d'agonistes ou d'antagonistes de l'activité phosphodiésterase comprenant au moins un des polypeptides selon les revendications 1 à 9, et un kit de test de phosphodiésterase radioactif ou IMPP-FP.

20

25

30

35

40

45

50

55

Figure 1




Figure 2




Figure 3




Figure 4

